About the Authors

Colton Linnertz

Affiliation Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America

Ann M. Saunders

Affiliations Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

Michael W. Lutz

Affiliation Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America

Donna M. Crenshaw

Affiliation Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America

Iris Grossman

Affiliation Cabernet Pharmaceuticals, Chapel Hill, North Carolina, United States of America

Daniel K. Burns

Affiliation Cabernet Pharmaceuticals, Chapel Hill, North Carolina, United States of America

Keith E. Whitfield

Affiliation Department of Psychology and Neuroscience, Duke University, Durham, North Carolina, United States of America

Michael A. Hauser

Affiliation Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States of America

Jeanette J. McCarthy

Affiliation Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America

Megan Ulmer

Affiliation Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States of America

Rand Allingham

Affiliation Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States of America

Kathleen A. Welsh-Bohmer

Affiliations Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, United States of America

Allen D. Roses

Affiliations Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America, Deane Drug Discovery Institute, Duke University Medical Center, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America

Ornit Chiba-Falek

o.chibafalek@duke.edu

Affiliations Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina, United States of America, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University, Durham, North Carolina, United States of America

Competing Interests

ADR is the CEO of Cabernet Pharmaceuticals, Inc., a pipeline pharmacogenetics consultation and project management company; and CEO of Zinfandel Pharmaceuticals, Inc., who is in an alliance with Takeda Pharmaceuticals to perform a delay of onset trial for dementias of the Alzheimer type. AMS, MWL and DMC are Members of the Joint Biomarker Committee for the Zinfandel-Takeda Alliance clinical trial and AMS is the spouse of ADR. DKB is a Senior VP of Zinfandel Pharmaceuticals. International Application No: PCT/US2009/053373: Method of identifying disease risk factors. Assignee: Zinfandel Pharmaceuticals, Inc; Inventor: Allen D. Roses. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AMS ADR OC-F. Performed the experiments: CL. Analyzed the data: AMS MWL DMC IG DKB ADR OC-F. Contributed reagents/materials/analysis tools: KEW MAH JJM MU RA KAW-B OC-F. Wrote the paper: AMS MWL DMC ADR OC-F.